Tolvaptan

Drug Class & Mechanism

• Brenner and Rector's The Kidney, p. 2266

Indications

1. Hyponatremia (hypervolemic or euvolemic)

• Specifically useful in SIADH, congestive heart failure, and cirrhosis-associated hyponatremia
• Effectively raises serum [Na+] in the majority of patients by stimulating aquaresis
• All 20+ clinical trials showed effective correction of hyponatremia vs. placebo
• Limitation: Does NOT improve primary outcomes (mortality, rehospitalization) - the EVEREST trial (4133 HF patients) showed no benefit on death/rehospitalization
• Brenner and Rector's The Kidney, p. 2265-2266 | NKF Primer on Kidney Diseases, 8e

2. Autosomal Dominant Polycystic Kidney Disease (ADPKD)

• Total kidney volume (TKV) growth: 2.8%/year (tolvaptan) vs. 5.5%/year (placebo), p <0.001
• eGFR decline reduced from 10.1 to 6.8 mL/min/1.73 m² over 3 years
• Also reduced kidney pain and albuminuria
• Approved for rapidly progressive ADPKD in Japan, Canada, EU, Australia (FDA required additional data)

• Confirmed slowing of eGFR decline in later-stage ADPKD
• Led to full FDA approval
• Brenner and Rector's The Kidney, p. 1999

Dosing (ADPKD)

• Common regimens: 45/15 mg, 60/30 mg, or 90/30 mg (morning/evening split)
• Brenner and Rector's The Kidney, p. 1999

Practical Rules for Vaptan Use in Hyponatremia

1. Initial correction goal: 6-8 mmol/L in 24 hours (not to exceed 10-12 mmol/L/24h or 18 mmol/L/48h to avoid osmotic demyelination syndrome)
2. Begin at lowest dose; allow patient to drink freely - do not co-administer fluid restriction during active vaptans therapy
3. Up-titrate dose if correction is <5 mmol/L in 24 hours
4. Generally ineffective if serum creatinine >2.5 mg/dL

Adverse Effects & Contraindications

Key Adverse Effects

• Aquaretic side effects: polyuria, polydipsia, thirst (common and expected)
• Hepatotoxicity (idiosyncratic DILI) - the major safety concern:
  • Transaminase elevations >3x ULN in 4.4% of tolvaptan vs. 1% of placebo patients (TEMPO 3:4)
  • 3/1271 patients met Hy's law criteria (serious hepatocellular toxicity)
  • Transaminase elevations are reversible upon drug discontinuation
  • REPRISE used more frequent monitoring (every 3-4 months); no Hy's law cases met criteria with that monitoring protocol
  • A 2025 review (PMID 39495155) specifically focused on tolvaptan idiosyncratic DILI in ADPKD
• Overly rapid Na+ correction - risk of osmotic demyelination syndrome (ODS/CPM) if not carefully monitored

Contraindications

• Cirrhosis or liver failure (hepatotoxicity risk; this is explicitly contraindicated for the ADPKD indication)
• Unable to perceive/respond to thirst
• Hypovolemic hyponatremia
• Urgent need for Na+ rise (acute severe symptomatic hyponatremia - use hypertonic saline instead)
• Harrison's Principles of Internal Medicine 22E, NKF Primer | Brenner and Rector's The Kidney

Recent Evidence (2024-2026)

• A 2024 systematic review and network meta-analysis (PMID 38873266) examined tolvaptan add-on therapy in acute heart failure - confirms Na+ correction benefit but no survival advantage
• A 2026 review (PMID 41212622) discusses SGLT2 inhibitors as a newer alternative for ADPKD, potentially complementary to tolvaptan
• Hepatotoxicity mechanisms remain an active research area (PMID 39495155, 2025)

Summary Table